A Delaware federal judge on Thursday granted British pharma company Vectura’s request for $10.5 million in supplemental damages in a case in which a jury found GlaxoSmithKline willfully infringed a patent covering inhalers, though the judge denied Vectura’s bid for an additional $33 million in enhanced damages…

Read this piece in its entirety at Law360.